Want to see NZ:PEB full AI Analyst Report?
Pacific Edge Limited (PEB) Stock Price & Analysis
PEB Stock Chart & Stats
- Day’s Range
- NZD 0.23 - NZD 0.24
- 52-Week Range
- NZD 0.14 - NZD 0.34
- Previous Close
- NZD 0.24
- Volume
- N/A
- Average Volume (3M)
- 975.21K
- Market Cap
- NZD 291.84M
- Enterprise Value
- NZD 171.45M
- Total Cash (Recent Filing)
- NZD 7.78M
- Total Debt (Recent Filing)
- NZD 1.28M
- Price to Earnings (P/E)
- ―
- Beta
- -1.16
- Next Earnings
- Dec 01, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Cxbladder Clinical Differentiation
A first-mover position in bladder cancer diagnostics, reinforced by proprietary urine tests and extensive clinical evidence, can support clinician adoption and payer discussions. This creates a durable foundation for commercial expansion if the company continues converting evidence into reimbursed testing volume.
APAC Volume And Product-mix Improvement
Rising APAC test volumes, stronger uptake of the higher-priced Triage Plus assay, and lower regional cash burn indicate improving unit economics. Progress toward direct-cost profitability could provide a more sustainable regional growth base and demonstrate that pricing and mix improvements can support margins.
Potential U.S. Medicare Coverage Expansion
Broader Medicare coverage would address a major adoption barrier by improving reimbursement access for Cxbladder in the U.S. Although the policy remains in draft form, a final favorable decision could materially expand eligible demand, support payer acceptance, and improve the scalability of the U.S. business.
Bears Say
Sharp Revenue And Gross-profit Deterioration
The latest deterioration in revenue and gross profit suggests that current test volumes, pricing, or cost absorption are not supporting a healthy operating model. Persistent losses reduce reinvestment capacity and make future growth more dependent on a successful commercial recovery rather than internally funded expansion.
Persistent Cash Burn
Continued negative operating and free cash flow shows that the business is not yet self-funding its operations. Ongoing cash consumption can constrain investment in sales and market access, while increasing reliance on capital management actions to maintain operating capacity through the next several quarters.
Shrinking Equity Cushion
Severe equity erosion leaves Pacific Edge with a much smaller capital cushion despite low leverage. A reduced equity base limits resilience against further operating losses and can narrow strategic flexibility, making it harder to fund commercial initiatives or absorb setbacks without additional shareholder support.
Pacific Edge Limited News
PEB FAQ
What was Pacific Edge Limited’s price range in the past 12 months?
What is Pacific Edge Limited’s market cap?
When is Pacific Edge Limited’s upcoming earnings report date?
How were Pacific Edge Limited’s earnings last quarter?
Is Pacific Edge Limited overvalued?
Does Pacific Edge Limited pay dividends?
What is Pacific Edge Limited’s EPS estimate?
How many shares outstanding does Pacific Edge Limited have?
What happened to Pacific Edge Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Pacific Edge Limited?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Pacific Edge Limited
Based in Dunedin, New Zealand, Pacific Edge Limited, established in 2001, operates as a cancer diagnostics firm. The company's core mission involves the research, development, and commercialization of advanced diagnostic and prognostic tools aimed at the early identification and ongoing management of various cancers. Its diagnostic solutions are accessible in New Zealand, the United States, Australia, and Singapore, with operations structured across Commercial and Research segments. A key offering is the Cxbladder suite, a collection of genomic urine tests specifically designed for detecting and managing bladder cancer. Within this suite, Cxbladder Resolve aids in identifying patients likely to present with more aggressive or advanced bladder cancer. Cxbladder Triage helps pinpoint individuals with haematuria who exhibit a low probability of bladder cancer, while Cxbladder Detect offers a non-invasive method for identifying bladder and other urinary tract cancers. Furthermore, Cxbladder Monitor facilitates continuous surveillance for disease recurrence in bladder cancer patients. Beyond its focus on bladder cancer, Pacific Edge is actively developing additional diagnostic innovations. These include Cxcolorectal, a prognostic gene signature for assessing outcomes in patients diagnosed with stage II or stage III colorectal cancers, alongside pipeline products targeting gastric, endometrial cancers, and melanoma.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Peter Meintjes
- Employees
- 114
- Website
- www.pacificedgedx.com
- Address
- Centre for Innovation, Dunedin, OT, 9016, NZ
Pacific Edge Limited (PEB) Earnings & Revenues
PEB Earnings Call
Earnings Call SentimentNeutral
The earnings call presents a mixed view, with notable strategic achievements and promising future prospects, particularly with the upcoming Contractor Advisory Committee. However, significant challenges remain due to reduced revenue, test volumes, and the impact of Medicare non-coverage, creating financial strains and operational hurdles.
View all NZ:PEB earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 6 | 10 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 5 | 0 | 7 |
